Published in Obstet Gynecol Int on April 28, 2010
Role of pelvic and para-aortic lymphadenectomy in abandoned radical hysterectomy in cervical cancer. World J Surg Oncol (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer (2001) 3.21
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol (2001) 1.64
An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol (2008) 1.43
A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol (2006) 1.25
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol (1999) 1.15
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys (2008) 1.10
The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol (2007) 1.10
Resection of bulky positive lymph nodes in patients with cervical carcinoma. Int J Gynecol Cancer (1995) 1.07
Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol (1999) 1.07
Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys (1983) 1.06
Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer (1998) 1.02
Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer (1991) 0.97
Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol (2008) 0.95
Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys (1989) 0.87
The abandoned radical hysterectomy: a Gynecologic Oncology Group Study. Gynecol Oncol (2000) 0.85
Outcomes of abandoned radical hysterectomy in patients with stages IB-IIA cervical cancer found to have positive nodes during the operation. Int J Gynecol Cancer (2005) 0.81
The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecol Oncol (2004) 0.80
Early invasive cervical cancer with pelvic lymph node involvement: to complete or not to complete radical hysterectomy? Gynecol Oncol (1990) 0.80
Early stage cervical cancer: aborted versus completed radical hysterectomy. Eur J Obstet Gynecol Reprod Biol (1992) 0.78
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol (2007) 1.59
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol (2007) 1.49
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer (2011) 1.47
An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol (2008) 1.43
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol (2004) 1.30
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol (2008) 1.15
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol (2006) 1.12
Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med (2012) 1.12
Self-assessment of resident surgical skills: is it feasible? Am J Obstet Gynecol (2005) 1.11
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer (2011) 1.11
A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol (2011) 1.09
Cervical cancer. J Natl Compr Canc Netw (2010) 1.07
Male circumcision and risk of HIV acquisition among MSM. AIDS (2011) 1.06
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer (2010) 1.05
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol (2011) 1.04
Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.00
Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol (2009) 0.99
Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. Arch Ophthalmol (2005) 0.97
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS). Am J Obstet Gynecol (2005) 0.97
Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J Altern Complement Med (2013) 0.96
A six-year study of surgical teaching and skills evaluation for obstetric/gynecologic residents in porcine and inanimate surgical models. Am J Obstet Gynecol (2005) 0.96
Pelvic exenteration in the age of modern chemoradiation. Gynecol Oncol (2011) 0.95
Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol (2011) 0.95
The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso. Int J Radiat Oncol Biol Phys (2002) 0.95
Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol (2003) 0.94
Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw (2014) 0.93
Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2009) 0.93
Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol (2010) 0.92
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer (2007) 0.92
Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt) (2010) 0.91
Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol Oncol (2005) 0.89
Intraperitoneal instillation of bupivacaine for reduction of postoperative pain after laparoscopic hysterectomy: a double-blind randomized controlled trial. J Minim Invasive Gynecol (2013) 0.88
Glassy cell carcinoma of the cervix revisited. Gynecol Oncol (2002) 0.88
Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control (2002) 0.86
Neutron radiotherapy for adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg (2013) 0.86
Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol (2011) 0.85
Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol (2006) 0.85
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
The emerging use of IMRT for treatment of cervical cancer. J Natl Compr Canc Netw (2010) 0.84
Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium. Gynecol Oncol (2005) 0.83
Cervical cancer. J Natl Compr Canc Netw (2008) 0.83
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol (2009) 0.82
Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet Gynecol (2014) 0.82
FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. Gynecol Oncol (2011) 0.82
Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer (2012) 0.81
Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol (2011) 0.81
Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative. Gynecol Oncol (2013) 0.80
The significance of psammoma bodies in screening cervical cytologic smears. Am J Obstet Gynecol (2003) 0.80
Guideline-inconsistent breast cancer screening for women over 50: a vignette-based survey. J Gen Intern Med (2013) 0.79
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. Gynecol Oncol (2009) 0.79
Surgical education: what role should gynecologic oncologists play? Gynecol Oncol (2008) 0.79
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia (2010) 0.79
Early stage endometrial cancer: to radiate or not to radiate--that is the question. Gynecol Oncol (2008) 0.78
Evaluation of postoperative fever: usefulness and cost-effectiveness of routine workup. Am J Obstet Gynecol (2003) 0.77
Nonparametric and Semiparametric Analysis of Current Status Data Subject to Outcome Misclassification. Stat Commun Infect Dis (2010) 0.77
Accuracy of ovarian and colon cancer risk assessments by U.S. physicians. J Gen Intern Med (2014) 0.77
Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey. Am J Prev Med (2012) 0.77
Training the next generation of minimally invasive surgeons. J Minim Invasive Gynecol (2009) 0.77
Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.77
Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 0.76
OP-1 injection increases VEGF expression but not angiogenesis in a rabbit model of distraction osteogenesis. Growth Factors (2008) 0.76
Uterine cancers. J Natl Compr Canc Netw (2006) 0.76
Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther (2013) 0.75
Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma. Transl Oncol (2012) 0.75
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers. Cancer Genet Cytogenet (2008) 0.75
Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2013) 0.75
What is the standard therapy for bulky stage IB cervical cancer? Int J Gynecol Cancer (2009) 0.75
Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy. Int J Gynecol Cancer (2016) 0.75
Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2004) 0.75
Surgical education for gynecologic oncologists. Gynecol Oncol (2009) 0.75
Quality measures in gynecologic cancers: what and when? Gynecol Oncol (2008) 0.75